Immunome, Inc.

Immunome, Inc.

IMNM·NASDAQ

$19.68

-0.66%
HealthcareBiotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.88B
EPS-2.4300
P/E Ratio-8.10
Earnings Date08/05/2026

imnm

Net Common Stock Issuance

Last Annual Value

640.36M

3-Year CAGR

2615%

5-Year CAGR

70%

10-Year CAGR

%

Immunome, Inc.

Immunome, Inc. Competitors Analysis of Net Common Stock Issuance

IMNM · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
640.36M
2560.6%88.1%N/A 
152.94M
996.5%N/AN/A
131.49M
3.2%-28.3%-2.6%
272.72M
N/AN/AN/A
275.84M
996.9%N/AN/A
2.39M
-77.7%-61.2%-16.2%
289.08M
36.0%41.4%N/A
BHVN logo
Biohaven Ltd.
NYSE:BHVN
189.31M
-8.0%N/AN/A
314.44M
23.0%N/A20.4%
Immunome, Inc.

Immunome, Inc. Fair Value Envelope

IMNM · NASDAQ

Our analysis suggests that IMNM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $19.68, this represents a potential HIDDEN relative to our calculated worth for Immunome, Inc..

Intrinsic Value
Current Price: $19.68